A strategy of being profitably smart and socially good to provide affordable access to advanced biopharmaceuticals for global patient populations.

A motivation to enter niche areas where we perceive the potential to moderate costs and widen patient access.

 A collaborative model that allows us to share risk and reward of drug development through research partnerships and extend our global footprint through local marketing alliances.

A relentless focus on chronic disease spaces like diabetes, cancer and autoimmune / inflammation.

A portfolio approach focused on chronic disease segments and integrating well validated target-to-clinic-to-counter capabilities.

An obligation to develop affordable blockbuster drugs with the potential to benefit a billion patients.